Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.03 USD | -0.66% | -0.33% | -28.03% |
Jan. 05 | CureVac Reports Positive Phase 2 Results for mRNA Covid Vaccines Developed With GSK | MT |
Jan. 05 | GSK, CureVac Plan Late-stage Study of COVID-19 mRNA Vaccine Candidates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.03% | 678M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
-8.77% | 11.06B |
- Stock
- Equities
- Stock CureVac N.V. - Nasdaq
- News CureVac N.V.
- CureVac N : to Refocus COVID-19 Vaccine Development Efforts to Second-Generation mRNA Candidate With GlaxoSmithKline